GlassScriptPhysician profile
Prasad V Katta
NPI 1235163866
$20,495.58
in general payments reported to CMS, 2019-2025
15 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,303 · 2021: $335 · 2022: $427 · 2023: $260 · 2024: $125 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,087.77 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $2,670.02 | 2019-2020 | |
| Novo Nordisk INC | $894.61 | 2019-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $739.76 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.27 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $162.59 | 2019 | |
| Medtronic Minimed, INC. | $147.38 | 2020 | |
| Allergan, INC. | $130.02 | 2020 | |
| Lilly USA, LLC | $121.58 | 2022-2024 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $111.43 | 2024 | Ilet Bionic Pancreas |
| Mannkind Corporation | $100.30 | 2019-2020 | |
| Genentech USA, INC. | $84.04 | 2019 | |
| Radius Health, INC. | $24.47 | 2019 | |
| Ibsa Pharma INC. | $24.17 | 2020 | |
| Abbott Laboratories | $16.17 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Katta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.